Download presentation
Presentation is loading. Please wait.
1
Analysis of Outcomes Using Low-Dose and Early Administration of Recombinant Activated Factor VII in Cardiac Surgery Jason Brase, MS, Brooke Finger, MS, Jianghua He, PhD, Katy Wirtz, RN, BSN, Lucy Stun, PharmD, Randy McMillen, Brigid Flynn, MD The Annals of Thoracic Surgery Volume 102, Issue 1, Pages (July 2016) DOI: /j.athoracsur Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions
2
Fig 1 Concomitant blood product administration in patients who received recombinant activated factor VII (n = 51). The Annals of Thoracic Surgery , 35-40DOI: ( /j.athoracsur ) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions
3
Fig 2 Total number of cardiac surgical study patients who had bleeding by definition (n = 378). Fifty-one (13%) patients who bled received recombinant activated factor VII (rFVIIa) with a nonprotocolized, liberal strategy of rFVIIa administration. The Annals of Thoracic Surgery , 35-40DOI: ( /j.athoracsur ) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.